Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device
A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery Device
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 26, 2006
CompletedFirst Posted
Study publicly available on registry
January 30, 2006
CompletedFebruary 2, 2021
March 1, 2015
January 26, 2006
February 1, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Intra-ocular pressure (IOP) level in the study eye.
Secondary Outcomes (4)
Successful eyedrop self-deliveries
Ease of eyedrop administration
Change in safety assessments throughout the study period
Subject preference for the method of drop delivery
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes
You may not qualify if:
- History of closed/barely open anterior chamber angle or a history of angle closure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 26, 2006
First Posted
January 30, 2006
Last Updated
February 2, 2021
Record last verified: 2015-03